JP2024041751A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024041751A5 JP2024041751A5 JP2023207912A JP2023207912A JP2024041751A5 JP 2024041751 A5 JP2024041751 A5 JP 2024041751A5 JP 2023207912 A JP2023207912 A JP 2023207912A JP 2023207912 A JP2023207912 A JP 2023207912A JP 2024041751 A5 JP2024041751 A5 JP 2024041751A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- c6orf106
- candidate compound
- increases
- decreases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 71
- 150000001875 compounds Chemical class 0.000 claims description 58
- 101000998434 Homo sapiens Protein ILRUN Proteins 0.000 claims description 42
- 102100033275 Protein ILRUN Human genes 0.000 claims description 41
- 230000004952 protein activity Effects 0.000 claims description 26
- 229920001184 polypeptide Polymers 0.000 claims description 16
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 16
- 102000006992 Interferon-alpha Human genes 0.000 claims description 13
- 108010047761 Interferon-alpha Proteins 0.000 claims description 13
- 239000012634 fragment Substances 0.000 claims description 12
- 230000007423 decrease Effects 0.000 claims description 11
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 7
- 101001011382 Homo sapiens Interferon regulatory factor 3 Proteins 0.000 claims description 7
- 102100029843 Interferon regulatory factor 3 Human genes 0.000 claims description 7
- 108090000467 Interferon-beta Proteins 0.000 claims description 7
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 7
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 7
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 claims description 7
- 208000036142 Viral infection Diseases 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 150000003384 small molecules Chemical class 0.000 claims description 4
- 230000009385 viral infection Effects 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 3
- 108091023037 Aptamer Proteins 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 108010032038 Interferon Regulatory Factor-3 Proteins 0.000 claims 6
- 102000007578 Interferon Regulatory Factor-3 Human genes 0.000 claims 6
- 102000003996 Interferon-beta Human genes 0.000 claims 6
- 230000001404 mediated effect Effects 0.000 claims 6
- 150000001413 amino acids Chemical group 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 description 15
- 102000040430 polynucleotide Human genes 0.000 description 15
- 239000002157 polynucleotide Substances 0.000 description 15
- 230000028993 immune response Effects 0.000 description 14
- 230000016396 cytokine production Effects 0.000 description 7
- 125000003275 alpha amino acid group Chemical group 0.000 description 6
- 208000023275 Autoimmune disease Diseases 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 241000700605 Viruses Species 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 description 2
- 230000007416 antiviral immune response Effects 0.000 description 2
- 230000007813 immunodeficiency Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 241001115070 Bornavirus Species 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 108091008102 DNA aptamers Proteins 0.000 description 1
- 241000711950 Filoviridae Species 0.000 description 1
- 102100026720 Interferon beta Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- 108091008103 RNA aptamers Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 108091008107 XNA aptamers Proteins 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000010468 interferon response Effects 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000030428 polyarticular arthritis Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000010472 type I IFN response Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2015905035A AU2015905035A0 (en) | 2015-12-04 | Regulation of cytokine production | |
| AU2015905035 | 2015-12-04 | ||
| JP2018529102A JP2019503998A (ja) | 2015-12-04 | 2016-12-02 | サイトカイン産生の調節 |
| PCT/AU2016/051192 WO2017091866A1 (en) | 2015-12-04 | 2016-12-02 | Regulation of cytokine production |
| JP2021177668A JP2022028689A (ja) | 2015-12-04 | 2021-10-29 | サイトカイン産生の調節 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021177668A Division JP2022028689A (ja) | 2015-12-04 | 2021-10-29 | サイトカイン産生の調節 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024041751A JP2024041751A (ja) | 2024-03-27 |
| JP2024041751A5 true JP2024041751A5 (https=) | 2024-08-22 |
Family
ID=58796001
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018529102A Pending JP2019503998A (ja) | 2015-12-04 | 2016-12-02 | サイトカイン産生の調節 |
| JP2021177668A Pending JP2022028689A (ja) | 2015-12-04 | 2021-10-29 | サイトカイン産生の調節 |
| JP2023207912A Pending JP2024041751A (ja) | 2015-12-04 | 2023-12-08 | サイトカイン産生の調節 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018529102A Pending JP2019503998A (ja) | 2015-12-04 | 2016-12-02 | サイトカイン産生の調節 |
| JP2021177668A Pending JP2022028689A (ja) | 2015-12-04 | 2021-10-29 | サイトカイン産生の調節 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20180362625A1 (https=) |
| EP (1) | EP3383408A4 (https=) |
| JP (3) | JP2019503998A (https=) |
| KR (1) | KR20180088455A (https=) |
| CN (1) | CN108601794A (https=) |
| AU (2) | AU2016363114B2 (https=) |
| CA (1) | CA3007287A1 (https=) |
| WO (1) | WO2017091866A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12059413B2 (en) | 2016-11-02 | 2024-08-13 | The Research Foundation For The State University Of New York | Methods of inhibiting viruses using compositions targeting TSG101-ubiquitin interaction |
| CN107964564B (zh) * | 2017-12-28 | 2020-09-11 | 中南大学湘雅医院 | 胶质瘤诊断标志物circ6:34606555|34606904及应用 |
| KR102805517B1 (ko) * | 2022-12-22 | 2025-05-12 | 주식회사 셀렉소바이오 | 강직성 척추염 진단용 조성물, 키트 및 이의 정보제공방법 |
| CN120189429B (zh) * | 2025-05-09 | 2026-02-27 | 中国科学院生物物理研究所 | 靶向C6orf223蛋白的抑制剂在制备治疗肿瘤药物中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1313313A (zh) * | 2000-03-10 | 2001-09-19 | 上海博德基因开发有限公司 | 一种新的多肽——人cdc4类似蛋白12和编码这种多肽的多核苷酸 |
| US20030013651A1 (en) * | 2001-03-22 | 2003-01-16 | Barnes-Jewish Hospital | Stimulation of osteogenesis using rank ligand fusion proteins |
| US20070224201A1 (en) * | 2002-10-02 | 2007-09-27 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| US8101741B2 (en) * | 2005-11-02 | 2012-01-24 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
| KR101629963B1 (ko) * | 2008-07-21 | 2016-06-14 | 경희대학교 산학협력단 | 염증성 질환 진단용 ｃＤＮＡ 마이크로어레이 칩 |
| CN101773668B (zh) * | 2009-01-09 | 2012-09-12 | 中国科学院上海生命科学研究院 | 一种抗病毒相关蛋白及其用途 |
-
2016
- 2016-12-02 AU AU2016363114A patent/AU2016363114B2/en active Active
- 2016-12-02 EP EP16869418.0A patent/EP3383408A4/en active Pending
- 2016-12-02 CA CA3007287A patent/CA3007287A1/en active Pending
- 2016-12-02 US US15/781,322 patent/US20180362625A1/en not_active Abandoned
- 2016-12-02 CN CN201680080143.5A patent/CN108601794A/zh active Pending
- 2016-12-02 KR KR1020187019002A patent/KR20180088455A/ko not_active Ceased
- 2016-12-02 JP JP2018529102A patent/JP2019503998A/ja active Pending
- 2016-12-02 WO PCT/AU2016/051192 patent/WO2017091866A1/en not_active Ceased
-
2021
- 2021-10-29 JP JP2021177668A patent/JP2022028689A/ja active Pending
-
2023
- 2023-07-14 AU AU2023204701A patent/AU2023204701A1/en active Pending
- 2023-12-08 JP JP2023207912A patent/JP2024041751A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024041751A5 (https=) | ||
| Tan et al. | When hepatitis B virus meets interferons | |
| Mitra et al. | Hepatitis B virus precore protein p22 inhibits alpha interferon signaling by blocking STAT nuclear translocation | |
| Moltedo et al. | Cutting edge: stealth influenza virus replication precedes the initiation of adaptive immunity | |
| US6846486B1 (en) | Method of treating allergy by administering an anti-histamine antibody | |
| Kapoor et al. | Strategies to eliminate HBV infection | |
| Tavares et al. | ACKR2 contributes to pulmonary dysfunction by shaping CCL5: CCR5-dependent recruitment of lymphocytes during influenza A infection in mice | |
| Annibali et al. | IFN-β and multiple sclerosis: from etiology to therapy and back | |
| Dianzani et al. | The biological basis for clinical use of interferon | |
| Lim et al. | Virus receptor trap neutralizes coxsackievirus in experimental murine viral myocarditis | |
| CN113769058A (zh) | 一种药物组合及其应用 | |
| Raghuvanshi et al. | Interferon production by Viral, Bacterial & Yeast system: A comparative overview in 2023 | |
| Zhu et al. | LincRNA‐EPS impairs host antiviral immunity by antagonizing viral RNA–PKR interaction | |
| JP2019503998A5 (https=) | ||
| Xu et al. | High-Affinity–Mediated Viral Entry Triggers Innate Affinity Escape Resulting in Type I IFN Resistance and Impaired T Cell Immunity | |
| CN107375908B (zh) | 干扰素κ在制备抗囊膜病毒药物方面的应用 | |
| JPWO2020065349A5 (https=) | ||
| WO2024067785A1 (zh) | 基于干扰素协同免疫检查点阻断抗体治疗慢性乙型肝炎 | |
| Valentine et al. | Cd8+ T Cell–Derived Ifn-Γ Prevents Infection by a Second Heterologous Virus | |
| US20040033209A1 (en) | Method of treating allergen induced airway disease | |
| CN107050431A (zh) | 流感样疾病的疗法 | |
| JP2010522728A5 (https=) | ||
| CN108721646B (zh) | 一种抑制病毒感染的方法及抗病毒药物 | |
| Takaoka | Interferons | |
| Zhang et al. | Antiviral activity of mink interferon alpha expressed in the yeast Pichia pastoris |